{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T21:33:45Z","timestamp":1781991225930,"version":"3.54.5"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,8,26]],"date-time":"2022-08-26T00:00:00Z","timestamp":1661472000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,26]],"date-time":"2022-08-26T00:00:00Z","timestamp":1661472000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"University of Pennsylvania Center for Health Incentives and Behavioral Economics"},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Science","doi-asserted-by":"crossref","award":["UL1TR000003"],"award-info":[{"award-number":["UL1TR000003"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Science","doi-asserted-by":"crossref","award":["UL1TR000003"],"award-info":[{"award-number":["UL1TR000003"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Science","doi-asserted-by":"crossref","award":["UL1TR000003"],"award-info":[{"award-number":["UL1TR000003"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Science","doi-asserted-by":"crossref","award":["UL1TR000003"],"award-info":[{"award-number":["UL1TR000003"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Harm Reduct J"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Emergency departments (EDs) are important venues for the distribution of naloxone to patients at high risk of opioid overdose, but less is known about patient perceptions on\u00a0naloxone or best practices for patient education and communication. Our aim was to conduct an in-depth exploration of knowledge and attitudes toward ED naloxone distribution among patients who\u00a0received a naloxone prescription.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We conducted semi-structured telephone interviews with 25 adult participants seen and discharged from three urban, academic EDs in Philadelphia, PA, with a naloxone\u00a0prescription between November 2020 and February 2021. Interviews focused on awareness of naloxone as well as attitudes and experiences receiving naloxone in the ED. We used thematic content analysis to identify key themes reflecting patient attitudes and experiences.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of the 25 participants, 72% had previously witnessed an overdose and 48% had personally experienced a non-fatal overdose. Nineteen participants (76%) self-disclosed a history of substance use or overdose, and one reported receiving an opioid prescription during their ED visit and no history of substance use. In interviews, we identified wide variability in participant levels of knowledge about overdose risk, the role of naloxone in reducing risk, and naloxone access. A subset of participants was highly engaged with community harm reduction resources and well versed in naloxone access and use. A second subset was familiar with naloxone, but largely obtained it through healthcare settings such as the ED, while a final group was largely unfamiliar with naloxone. While most participants expressed positive attitudes about receiving naloxone from the ED, the quality of discussions with ED providers was variable, with some participants not even aware they were receiving a naloxone prescription until discharge.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Naloxone prescribing in the ED was acceptable and valued by most participants, but there are missed opportunities for communication and education. These findings underscore the critical role that EDs play in mitigating risks for patients who are not engaged with other healthcare or community health providers and can inform future work about the effective implementation of harm reduction strategies in ED settings.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12954-022-00677-7","type":"journal-article","created":{"date-parts":[[2022,8,26]],"date-time":"2022-08-26T09:02:44Z","timestamp":1661504564000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Patient perspectives on naloxone receipt in the emergency department: a qualitative exploration"],"prefix":"10.1186","volume":"19","author":[{"given":"Margaret","family":"Lowenstein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hareena K.","family":"Sangha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Spadaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanmarie","family":"Perrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Kit","family":"Delgado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anish K.","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,26]]},"reference":[{"key":"677_CR1","unstructured":"Centers for Disease Control and Prevention. Understanding the epidemic. Centers for disease control and prevention, national center for injury prevention and control. https:\/\/www.cdc.gov\/drugoverdose\/index.html (2020). Accessed 7 Jul 2021."},{"issue":"S2","key":"677_CR2","doi-asserted-by":"publisher","first-page":"S95","DOI":"10.2105\/AJPH.2022.306804","volume":"112","author":"R McNeil","year":"2022","unstructured":"McNeil R, Jauffret-Roustide M, Hansen H. Reducing drug-related harms and promoting health justice worldwide during and after COVID-19: an AJPH supplement. Am J Public Health. 2022;112(S2):S95\u20138.","journal-title":"Am J Public Health"},{"key":"677_CR3","unstructured":"Centers for Disease Control and Prevention. Increase in fatal drug overdoses across the United States driven by synthetic opioids before and during the COVID-19 pandemic. https:\/\/emergency.cdc.gov\/han\/2020\/han00438.asp (2020). Accessed October, 2021."},{"key":"677_CR4","unstructured":"Centers for Disease Control and Prevention. Overdose prevention. https:\/\/www.cdc.gov\/drugoverdose\/prevention\/index.html (2017). Updated 31 Aug 2017. Accessed 15 Dec 2018."},{"key":"677_CR5","doi-asserted-by":"publisher","first-page":"f174","DOI":"10.1136\/bmj.f174","volume":"346","author":"AY Walley","year":"2013","unstructured":"Walley AY, Xuan Z, Hackman HH, et al. Opioid overdose rates and implementation of overdose education and nasal naloxone distribution in Massachusetts: interrupted time series analysis. BMJ. 2013;346:f174.","journal-title":"BMJ"},{"issue":"1","key":"677_CR6","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s13722-016-0068-3","volume":"12","author":"T Kerensky","year":"2017","unstructured":"Kerensky T, Walley AY. Opioid overdose prevention and naloxone rescue kits: what we know and what we don\u2019t know. Addict Sci Clin Pract. 2017;12(1):4.","journal-title":"Addict Sci Clin Pract"},{"key":"677_CR7","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.drugpo.2017.06.005","volume":"46","author":"N Fairbairn","year":"2017","unstructured":"Fairbairn N, Coffin PO, Walley AY. Naloxone for heroin, prescription opioid, and illicitly made fentanyl overdoses: challenges and innovations responding to a dynamic epidemic. Int J Drug Policy. 2017;46:172\u20139.","journal-title":"Int J Drug Policy"},{"key":"677_CR8","volume-title":"Community management of opioid overdose","author":"World Health Organization","year":"2014","unstructured":"World Health Organization. Community management of opioid overdose. Geneva: Switzerland; 2014."},{"issue":"3","key":"677_CR9","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1097\/ADM.0000000000000034","volume":"8","author":"AK Clark","year":"2014","unstructured":"Clark AK, Wilder CM, Winstanley EL. A systematic review of community opioid overdose prevention and naloxone distribution programs. J Addict Med. 2014;8(3):153\u201363.","journal-title":"J Addict Med"},{"issue":"1","key":"677_CR10","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s40621-015-0041-8","volume":"2","author":"RE Giglio","year":"2015","unstructured":"Giglio RE, Li G, DiMaggio CJ. Effectiveness of bystander naloxone administration and overdose education programs: a meta-analysis. Inj Epidemiol. 2015;2(1):10.","journal-title":"Inj Epidemiol"},{"issue":"7","key":"677_CR11","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1111\/add.13326","volume":"111","author":"R McDonald","year":"2016","unstructured":"McDonald R, Strang J. Are take-home naloxone programmes effective? Systematic review utilizing application of the Bradford Hill criteria. Addiction. 2016;111(7):1177\u201387.","journal-title":"Addiction"},{"issue":"4","key":"677_CR12","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1111\/dar.12812","volume":"37","author":"R Dwyer","year":"2018","unstructured":"Dwyer R, Olsen A, Fowlie C, et al. An overview of take-home naloxone programs in Australia. Drug Alcohol Rev. 2018;37(4):440\u20139.","journal-title":"Drug Alcohol Rev"},{"key":"677_CR13","unstructured":"European Monitoring Centre for Drugs and Drug Addiction. Take-home naloxone. https:\/\/www.emcdda.europa.eu\/publications\/topic-overviews\/take-home-naloxone#section6. Accessed 10 Aug 2022."},{"issue":"5","key":"677_CR14","doi-asserted-by":"publisher","first-page":"e193209","DOI":"10.1001\/jamanetworkopen.2019.3209","volume":"2","author":"S Follman","year":"2019","unstructured":"Follman S, Arora VM, Lyttle C, Moore PQ, Pho MT. Naloxone prescriptions among commercially insured individuals at high risk of opioid overdose. JAMA Netw Open. 2019;2(5):e193209.","journal-title":"JAMA Netw Open"},{"issue":"20","key":"677_CR15","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1001\/jama.2018.4867","volume":"319","author":"JM Adams","year":"2018","unstructured":"Adams JM. Increasing naloxone awareness and use: the role of health care practitioners. JAMA. 2018;319(20):2073\u20134.","journal-title":"JAMA"},{"key":"677_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.annemergmed.2021.04.023","author":"K Hawk","year":"2021","unstructured":"Hawk K, Hoppe J, Ketcham E, et al. Consensus recommendations on the treatment of opioid use disorder in the emergency department. Ann Emerg Med. 2021. https:\/\/doi.org\/10.1016\/j.annemergmed.2021.04.023","journal-title":"Ann Emerg Med"},{"issue":"3","key":"677_CR17","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.annemergmed.2018.08.439","volume":"73","author":"EA Samuels","year":"2019","unstructured":"Samuels EA, D\u2019Onofrio G, Huntley K, et al. A quality framework for emergency department treatment of opioid use disorder. Ann Emerg Med. 2019;73(3):237\u201347.","journal-title":"Ann Emerg Med"},{"key":"677_CR18","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.ajem.2021.03.056","volume":"47","author":"AS Kilaru","year":"2021","unstructured":"Kilaru AS, Liu M, Gupta R, et al. Naloxone prescriptions following emergency department encounters for opioid use disorder, overdose, or withdrawal. Am J Emerg Med. 2021;47:154\u20137.","journal-title":"Am J Emerg Med"},{"key":"677_CR19","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.ypmed.2018.06.005","volume":"114","author":"E Behar","year":"2018","unstructured":"Behar E, Bagnulo R, Coffin PO. Acceptability and feasibility of naloxone prescribing in primary care settings: a systematic review. Prev Med. 2018;114:79\u201387.","journal-title":"Prev Med"},{"issue":"5","key":"677_CR20","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1370\/afm.1972","volume":"14","author":"E Behar","year":"2016","unstructured":"Behar E, Rowe C, Santos GM, Murphy S, Coffin PO. Primary care patient experience with naloxone prescription. Ann Fam Med. 2016;14(5):431\u20136.","journal-title":"Ann Fam Med"},{"issue":"3","key":"677_CR21","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s11606-016-3895-8","volume":"32","author":"SR Mueller","year":"2017","unstructured":"Mueller SR, Koester S, Glanz JM, Gardner EM, Binswanger IA. Attitudes toward naloxone prescribing in clinical settings: a qualitative study of patients prescribed high dose opioids for chronic non-cancer pain. J Gen Intern Med. 2017;32(3):277\u201383.","journal-title":"J Gen Intern Med"},{"issue":"6","key":"677_CR22","first-page":"364","volume":"47","author":"M Funke","year":"2021","unstructured":"Funke M, Kaplan MC, Glover H, et al. Increasing naloxone prescribing in the emergency department through education and electronic medical record work-aids. Jt Comm J Qual Patient Saf. 2021;47(6):364\u201375.","journal-title":"Jt Comm J Qual Patient Saf"},{"issue":"9","key":"677_CR23","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1111\/add.14635","volume":"114","author":"R Marino","year":"2019","unstructured":"Marino R, Landau A, Lynch M, Callaway C, Suffoletto B. Do electronic health record prompts increase take-home naloxone administration for emergency department patients after an opioid overdose? Addiction. 2019;114(9):1575\u201381.","journal-title":"Addiction"},{"issue":"2","key":"677_CR24","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/acem.13545","volume":"26","author":"EA Samuels","year":"2019","unstructured":"Samuels EA, Baird J, Yang ES, Mello MJ. Adoption and utilization of an emergency department naloxone distribution and peer recovery coach consultation program. Acad Emerg Med Off J Soc Acad Emerg Med. 2019;26(2):160\u201373.","journal-title":"Acad Emerg Med Off J Soc Acad Emerg Med"},{"key":"677_CR25","doi-asserted-by":"publisher","first-page":"108009","DOI":"10.1016\/j.drugalcdep.2020.108009","volume":"213","author":"Y Chen","year":"2020","unstructured":"Chen Y, Wang Y, Nielsen S, Kuhn L, Lam T. A systematic review of opioid overdose interventions delivered within emergency departments. Drug Alcohol Depend. 2020;213:108009.","journal-title":"Drug Alcohol Depend"},{"issue":"5","key":"677_CR26","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1111\/acem.14197","volume":"28","author":"K Hawk","year":"2021","unstructured":"Hawk K, Grau LE, Fiellin DA, et al. A qualitative study of emergency department patients who survived an opioid overdose: perspectives on treatment and unmet needs. Acad Emerg Med Off J Soc Acad Emerg Med. 2021;28(5):542\u201352.","journal-title":"Acad Emerg Med Off J Soc Acad Emerg Med"},{"issue":"6","key":"677_CR27","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1093\/intqhc\/mzm042","volume":"19","author":"A Tong","year":"2007","unstructured":"Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. Int J Qual Health Care. 2007;19(6):349\u201357.","journal-title":"Int J Qual Health Care"},{"key":"677_CR28","unstructured":"Philadelphia Department of Public Health. 2016 Overdoses From Opioids in Philadelphia. CHART Web site. http:\/\/www.phila.gov\/health\/pdfs\/chart%20v2e7.pdf (2017). Accessed Oct 2021."},{"key":"677_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.annemergmed.2021.10.012","author":"M Lowenstein","year":"2021","unstructured":"Lowenstein M, Perrone J, Xiong RA, et al. Sustained implementation of a multicomponent strategy to increase emergency department-initiated interventions for opioid use disorder. Ann Emerg Med. 2021. https:\/\/doi.org\/10.1016\/j.annemergmed.2021.10.012.","journal-title":"Ann Emerg Med"},{"issue":"9","key":"677_CR30","first-page":"1","volume":"17","author":"DA Asch","year":"2012","unstructured":"Asch DA, Volpp KG. On the way to health. LDI Issue Brief. 2012;17(9):1\u20134.","journal-title":"LDI Issue Brief"},{"issue":"3","key":"677_CR31","first-page":"149","volume":"79","author":"P Khatiwoda","year":"2018","unstructured":"Khatiwoda P, Proeschold-Bell RJ, Meade CS, Park LP, Proescholdbell S. Facilitators and barriers to naloxone kit use among opioid-dependent patients enrolled in medication assisted therapy clinics in North Carolina. N C Med J. 2018;79(3):149\u201355.","journal-title":"N C Med J"},{"issue":"3","key":"677_CR32","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s11524-019-00349-1","volume":"96","author":"E Donovan","year":"2019","unstructured":"Donovan E, Case P, Bratberg JP, et al. Beliefs associated with pharmacy-based naloxone: a qualitative study of pharmacy-based naloxone purchasers and people at risk for opioid overdose. J Urban Health Bull N Y Acad Med. 2019;96(3):367\u201378.","journal-title":"J Urban Health Bull N Y Acad Med"},{"key":"677_CR33","volume-title":"Nicholas, qualitative research in health care","author":"CM Pope","year":"2000","unstructured":"Pope CM. Nicholas, qualitative research in health care. Hoboken: BMJ Books; 2000."},{"key":"677_CR34","unstructured":"Levine R. Naloxone prescription for overdose prevention. In: Health Do, 2018."},{"issue":"16","key":"677_CR35","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1001\/jama.2015.3474","volume":"313","author":"G D\u2019Onofrio","year":"2015","unstructured":"D\u2019Onofrio G, O\u2019Connor PG, Pantalon MV, et al. Emergency department-initiated buprenorphine\/naloxone treatment for opioid dependence: a randomized clinical trial. JAMA. 2015;313(16):1636\u201344.","journal-title":"JAMA"},{"key":"677_CR36","doi-asserted-by":"publisher","DOI":"10.1111\/acem.13367","author":"A Martin","year":"2017","unstructured":"Martin A, Mitchell A, Wakeman S, White B, Raja A. Emergency department treatment of opioid addiction: an opportunity to lead. Acad Emerg Med Off J Soc Acad Emerg Med. 2017. https:\/\/doi.org\/10.1111\/acem.13367.","journal-title":"Acad Emerg Med Off J Soc Acad Emerg Med"},{"issue":"4","key":"677_CR37","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1111\/1742-6723.13925","volume":"34","author":"E Black","year":"2022","unstructured":"Black E, Monds LA, Chan B, et al. Overdose and take-home naloxone in emergency settings: a pilot study examining feasibility of delivering brief interventions addressing overdose prevention with \u2018take-home naloxone\u2019 in emergency departments. Emerg Med Australas. 2022;34(4):509\u201318.","journal-title":"Emerg Med Australas"},{"key":"677_CR38","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s40814-020-00626-w","volume":"6","author":"M Jones","year":"2020","unstructured":"Jones M, Bell F, Benger J, et al. Protocol for take-home naloxone in multicentre emergency (TIME) settings: feasibility study. Pilot Feasibility Stud. 2020;6:96.","journal-title":"Pilot Feasibility Stud"},{"issue":"13","key":"677_CR39","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1007\/s40265-019-01154-5","volume":"79","author":"J Strang","year":"2019","unstructured":"Strang J, McDonald R, Campbell G, et al. Take-home naloxone for the emergency interim management of opioid overdose: the public health application of an emergency medicine. Drugs. 2019;79(13):1395\u2013418.","journal-title":"Drugs"},{"key":"677_CR40","unstructured":"Harm Reduction Coalition. Overdose Risks and Prevention. Opioid Overdose Basics Training Guide Web site. https:\/\/harmreduction.org\/issues\/overdose-prevention\/overview\/overdose-basics\/opioid-od-risks-prevention\/ (2020). Accessed 12 Jul 2021."},{"issue":"19","key":"677_CR41","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1056\/NEJMp2103274","volume":"384","author":"KL Sue","year":"2021","unstructured":"Sue KL, Fiellin DA. Bringing harm reduction into health policy\u2014combating the overdose crisis. N Engl J Med. 2021;384(19):1781\u20133.","journal-title":"N Engl J Med"},{"key":"677_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajem.2019.02.025","author":"M Lowenstein","year":"2019","unstructured":"Lowenstein M, Kilaru A, Perrone J, et al. Barriers and facilitators for emergency department initiation of buprenorphine: a physician survey. Am J Emerg Med. 2019. https:\/\/doi.org\/10.1016\/j.ajem.2019.02.025.","journal-title":"Am J Emerg Med"},{"issue":"18","key":"677_CR43","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1056\/NEJMc1809521","volume":"379","author":"UG Khatri","year":"2018","unstructured":"Khatri UG, Viner K, Perrone J. Lethal fentanyl and cocaine intoxication. N Engl J Med. 2018;379(18):1782.","journal-title":"N Engl J Med"},{"issue":"1\u20132","key":"677_CR44","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.drugalcdep.2013.02.018","volume":"131","author":"LC van Boekel","year":"2013","unstructured":"van Boekel LC, Brouwers EP, van Weeghel J, Garretsen HF. Stigma among health professionals towards patients with substance use disorders and its consequences for healthcare delivery: systematic review. Drug Alcohol Depend. 2013;131(1\u20132):23\u201335.","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"677_CR45","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s11606-020-06201-6","volume":"36","author":"D Motavalli","year":"2021","unstructured":"Motavalli D, Taylor JL, Childs E, et al. \u201cHealth is on the back burner:\u201d multilevel barriers and facilitators to primary care among people who inject drugs. J Gen Intern Med. 2021;36(1):129\u201337.","journal-title":"J Gen Intern Med"},{"key":"677_CR46","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.drugalcdep.2019.01.037","volume":"198","author":"DL Biancarelli","year":"2019","unstructured":"Biancarelli DL, Biello KB, Childs E, et al. Strategies used by people who inject drugs to avoid stigma in healthcare settings. Drug Alcohol Depend. 2019;198:80\u20136.","journal-title":"Drug Alcohol Depend"}],"container-title":["Harm Reduction Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-022-00677-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12954-022-00677-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-022-00677-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,26]],"date-time":"2023-11-26T06:06:32Z","timestamp":1700978792000},"score":1,"resource":{"primary":{"URL":"https:\/\/harmreductionjournal.biomedcentral.com\/articles\/10.1186\/s12954-022-00677-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,26]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["677"],"URL":"https:\/\/doi.org\/10.1186\/s12954-022-00677-7","relation":{},"ISSN":["1477-7517"],"issn-type":[{"value":"1477-7517","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,26]]},"assertion":[{"value":"19 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Institutional Review Board of the University of Pennsylvania (#842821).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no known competing financial interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"97"}}